Alcobra ltd (adhd) short interest up 47.8% in february

Alcobra Ltd (NASDAQ:ADHD) was the target of a large increase in short interest in the month of February. National health information As of February 15th, there was short interest totalling 1,115,643 shares, an increase of 47.8% from the January 31st total of 754,914 shares. Health information service Based on an average trading volume of 1,490,584 shares, the short-interest ratio is presently 0.7 days. Health and fitness information Currently, 5.5% of the shares of the company are sold short.

Several hedge funds have recently added to or reduced their stakes in the company. Health information online Stifel Financial Corp boosted its position in Alcobra by 34.2% in the second quarter. Information on health Stifel Financial Corp now owns 62,000 shares of the company’s stock worth $278,000 after buying an additional 15,800 shares during the period. Definition of health information exchange J. Information about world health day Goldman & Co LP bought a new position in Alcobra during the fourth quarter worth about $546,000. Information about healthy food and junk food Palo Alto Investors LLC boosted its position in Alcobra by 7.3% in the second quarter. Information about healthy eating Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares during the period. History of health information exchange Royce & Associates LP boosted its position in Alcobra by 367.2% in the fourth quarter. Health information exchange definition Royce & Associates LP now owns 645,055 shares of the company’s stock worth $1,355,000 after buying an additional 507,000 shares during the period. Health information resources Finally, Kingdon Capital Management L.L.C. What is health information management boosted its position in Alcobra by 63.8% in the fourth quarter. Information about world health organisation Kingdon Capital Management L.L.C. Health information database now owns 650,000 shares of the company’s stock worth $1,365,000 after buying an additional 253,200 shares during the period. Information about health and safety Hedge funds and other institutional investors own 63.20% of the company’s stock.

Shares of Alcobra ( NASDAQ:ADHD) opened at 1.34 on Friday. Information about health and medicine The firm’s 50-day moving average is $1.22 and its 200 day moving average is $2.54. Components of health information systems The firm’s market capitalization is $36.93 million. Health and medicine information Alcobra has a 52 week low of $0.83 and a 52 week high of $5.75.

Several analysts have commented on the stock.


Health information exchange organizations Roth Capital upgraded shares of Alcobra from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Thursday, February 9th. Information about healthy food Zacks Investment Research upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, January 24th. Health information news Jefferies Group LLC cut shares of Alcobra from a “buy” rating to a “hold” rating and decreased their price objective for the company from $6.00 to $1.25 in a research note on Wednesday, January 18th. Human health information Cantor Fitzgerald set a $2.00 price objective on shares of Alcobra and gave the company a “hold” rating in a research note on Tuesday, January 17th. Health information systems degree Finally, Stifel Nicolaus set a $2.00 price objective on shares of Alcobra and gave the company a “hold” rating in a research note on Tuesday, January 17th. Health information exchange market One research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. Information about health care Alcobra has an average rating of “Hold” and a consensus price target of $2.02.

“[[title]]” was originally posted by [[site]] and is the sole property of of [[site]]. Information about health is wealth If you are reading this report on another website, it was copied illegally and reposted in violation of U.S. Information on health and medicine and international copyright & trademark laws. E health information management The correct version of this report can be read at [[permalink]].

Alcobra Ltd is an Israel-based Biopharmaceutical company. Health information sources It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Health information exchange standards Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Leave a Reply

Your email address will not be published. Required fields are marked *